Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety and Efficacy of Riliprubart, an Activated C1s-complement Inhibitor in CIDP: 76-week Phase Two Trial Results

Author:Querol, Luis   Lewis, Richard A.   Hartung, Hans-Peter   van Doorn, Pieter A.   Lin, Jie   Dionne, Annie   Attarian, Shahram   Wallstroem, Erik   Auwarter, Kristen   Lu, Yi   Alonso-Alonso, Miguel   Atassi, Nazem   Hughes, Richard A. C.   

Session Name:S2: Updates on Motor Neuron and Peripheral Nerve Disorders  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S2.008  

Author Institution:Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain  Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Madrid, Spain, Spain  Department of Neurology, Cedars Sinai Medical Center, Los Angeles, CA, USA, CA  Department of Neurology, Faculty of Medicine, Heinrich-Heine-University, Düsseldorf, Germany  Brain and Mind Center, University of Sydney, Sydney, NSW, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  Department of Neurology, Palacky University Olomouc, Olomouc, The Czech Republic, Dusseldorf, Germany  Erasmus MC, University Medical Center, Rotterdam, The Netherlands, Netherlands  Department of Neurology and Rare Disease Center, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China, People's Republic of  CHU de Quebec Universite Laval, Quebec, Canada, QC, Canada  Neuromuscular Disease and ALS Reference Center, Timone University Hospital, Aix-Marseille University, CHU Timone, Marseille Cedex 05, France, France  Sanofi R&D, Neurology Development, Cambridge, MA, USA, Cambridge, MA  Sanofi, USA, MA  Sanofi R&D, Biostatistics and Programming, Cambridge, MA, USA, CA  Sanofi R&D, Neurology Development, Cambridge, MA, USA, MA  UCL Queen Square Institute of Neurology, University College London, London, UK, United Kingdom  

Efficacy and Safety of Frexalimab in Participants With Relapsing Multiple Sclerosis: 3-Year Results From the Phase 2 Open-label Extension

Author:Vermersch, Patrick   Krieger, Stephen   Wiendl, Heinz   Granziera, Cristina   Mao-Draayer, Yang   Cutter, Gary   Kalbus, Oleksandr   Staikov, Ivan   Dufek, Michal   Montalban, Xavier   Saubadu, Stephane   Luo, Xiaodong   Smyth, Brendan   Djukic, Biljana   Truffinet, Philippe   Wallstroem, Erik   Giovannoni, Gavin   

Session Name:P7: Multiple Sclerosis: Clinical Trials 1  

Topic:Multiple Sclerosis  

Program Number:P7.003  

Author Institution:University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France, Lille, France  Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, United States, New York, NY  Department of Neurology and Neurophysiology, University of Freiburg, Freiburg, Germany  Brain & Mind Institute, University of Sydney, Sydney, Australia, Freiburg im Breisgau, Germany  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Autoimmunity Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States, Oklahoma City, OK  Department of Biostatistics, UAB School of Public Health, Birmingham, AL, United States, Birmingham, AL  Department of Neurology, Dnipro State Medical University, Dnipro, Ukraine, Dnipro, Ukraine  Clinic of Neurology and Sleep Medicine, Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria, Sofia, Bulgaria  First Department of Neurology, St. Anne’s University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic  Multiple Sclerosis Centre of Catalonia, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain , Barcelona, Spain  Sanofi, Gentilly, France, Chilly Mazarin, France  Sanofi, Morristown, NJ, United States, Morristown, NJ  Sanofi, Cambridge, MA, United States, Cambridge, MA  Queen Mary University of London, London, United Kingdom, London, United Kingdom